Victor Moyo
Chief Tech/Sci/R&D Officer at TRAWS PHARMA, INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steven Fruchtman | M | 73 | 9 years | |
Mark Guerin | M | 55 | 11 years | |
James Marino | M | 74 | 9 years | |
Doris Peterkin | F | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 14 years |
Joslyn Dobson | F | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 14 years |
Jack Stover | M | 69 | 8 years | |
Mary Shoemaker | F | 63 | 4 years | |
Trafford Clarke | M | 66 | 2 years | |
Bruce Downey | M | 76 |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 13 years |
Elena Prokupets | M | 69 |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
Jay L. Eastman | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
Kenneth Anderson | M | 72 |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 14 years |
Nikhil C. Munshi | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
Jooeun Bae | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
Matthew Parris | M | - | 6 years | |
Meena Arora | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Viren Mehta | M | 74 | 20 years | |
Jerome Groopman | M | 72 | 11 years | |
Peter Atadja | M | 64 | 2 years | |
Marc A. Cohen | M | 61 |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 8 years |
Adar Makovski Silverstein | M | - | 2 years | |
Michael Saunders | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 22 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Victor Moyo
- Personal Network